Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Julia Murphy

Physician Assistant, Medical Newport Beach, CA Physician Assistant

NPI 1619566726 CMS profile 11280973

520 Superior Ave Ste 150, Newport Beach, CA 92663

Open in the dashboard

General payments

$10,346

369 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julia Murphy of Newport Beach, CA is reported in the CMS Open Payments database as having received $10,346 across 369 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,014 77
2024 General $3,003 109
2023 General $1,441 62
2022 General $1,834 118
2021 General $54 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julia Murphy
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Julia Murphy were reported at $4,014. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Julia Murphy Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $54 $156 $41–$563 $132
2022 $1,834 $185 $55–$649 $149
2023 $1,441 $199 $58–$717 $160
2024 $3,003 $206 $62–$740 $164
2025 $4,014 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Insulet Corporation $2,251 19 payments
  2. Medtronic, Inc. $1,579 36 payments
  3. Novo Nordisk Inc $1,060 33 payments
  4. Lilly USA, LLC $842 47 payments
  5. Corcept Therapeutics $829 17 payments
  6. Mannkind Corporation $815 53 payments
  7. Antares Pharma, Inc. $499 49 payments
  8. Dexcom, Inc. $307 9 payments
  9. Amgen Inc. $246 15 payments
  10. Xeris Pharmaceuticals, Inc. $224 7 payments
  11. Other $1,694 84 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,636 353 payments
  2. Travel and Lodging $2,616 12 payments
  3. Gift $59 1 payment
  4. Education $35 3 payments
Products named General payments · program years 2021–2025
  1. Omnipod $2,251 19 payments
  2. MINIMED 780G $1,503 31 payments
  3. Korlym $829 17 payments
  4. AFREZZA $815 53 payments
  5. Ozempic $709 21 payments
  6. NOCDURNA $499 49 payments
  7. XYOSTED $499 49 payments
  8. MOUNJARO $488 21 payments
  9. TLANDO $322 29 payments
  10. RYBELSUS $266 12 payments
  11. Other $3,387 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

2,930

Median for Physician Assistant: 241

Drug cost

$1,866,435

Median for Physician Assistant: $4,110

Branded share of claims

72.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 367 $490,170
Mounjaro Tirzepatide Brand 321 $427,746
Jardiance Empagliflozin Brand 155 $185,069
Farxiga Dapagliflozin Propanediol Brand 81 $86,515
Rybelsus Semaglutide Brand 38 $73,735
Trulicity Dulaglutide Brand 56 $73,511
Afrezza Insulin Regular, Human Brand 36 $58,173
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 49 $50,413
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 28 $40,831
Tresiba Flextouch U-200 Insulin Degludec Brand 31 $40,827

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $430
$430 — —
AFREZZA
  • Mannkind Corporation $263
$263 36 —
Wegovy
  • Novo Nordisk Inc $171
$171 26 —
MOUNJARO
  • Lilly USA, LLC $145
$145 321 —
RECORLEV
  • Xeris Pharmaceuticals, Inc. $139
$139 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

369 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record